8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Apr 1, 2026·SEC
Zymeworks Inc.(ZYME)Earnings, Financials & Key Ratios
ZYME•NASDAQ
Price updated Jun 19, 2026
AboutZymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.Show more
- Revenue$106M+38.9%
- EBITDA-$81M+35.3%
- Net Income-$81M+33.9%
- EPS (Diluted)-1.08+33.3%
- Gross Margin100%
- EBITDA Margin-76.84%+53.4%
- Operating Margin-87.33%+51.4%
- Net Margin-76.56%+52.4%
- ROE-26.72%+12.5%
ZYME Key Insights
Zymeworks Inc. (ZYME) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 22.2%
✗Weaknesses
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ZYME posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ZYME Price & Volume
Zymeworks Inc. (ZYME) stock price & volume — 10-year historical chart
Loading chart...
ZYME Growth Metrics
Zymeworks Inc. (ZYME) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years27.06%
5 Years22.16%
3 Years-36.43%
TTM-12.98%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM9.7%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM8.05%
Return on Capital
10 Years-32.9%
5 Years-21.87%
3 Years-27.78%
Last Year-27.26%
ZYME Recent Earnings
Zymeworks Inc. (ZYME) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.59-490.0%
$0.10
Rev
$2M-90.1%
$24M
Q2 2026
Mar 2, 2026Metric
Actual
Est
EPS
$0.55-57.1%
$0.35
Rev
$3M-86.9%
$19M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.26+13.3%
$0.30
Rev
$28M+41.7%
$19M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.03+105.8%
$0.52
Rev
$49M+89.3%
$26M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.59vs $0.10-490.0% | $2Mvs $24M-90.1% |
| Q2 2026 | Mar 2, 2026 | $0.55vs $0.35-57.1% | $3Mvs $19M-86.9% |
| Q4 2025 | Nov 6, 2025 | $0.26vs $0.30+13.3% | $28Mvs $19M+41.7% |
| Q3 2025 | Aug 7, 2025 | $0.03vs $0.52+105.8% | $49Mvs $26M+89.3% |
Based on last 12 quarters of dataView full earnings history →
ZYME Peer Comparison
Zymeworks Inc. (ZYME) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 MRUS | 6.83B | 90.00 | -26.87 | -12.38% | -6.54% | -50.62% | 0.02 | |
 AGIO | 2.03B | 34.16 | -4.80 | 48.03% | -6.4% | -34.11% | 0.05 | |
 TPST | 5.46M | 1.23 | -0.19 | -7.3% | 1.22 | |||
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% | ||
 ARVN | 494.88M | 7.67 | -5.99 | -0.3% | -247.54% | -44.39% | 0.02 | |
 BCAB | 4.61M | 3.66 | -0.07 | -81.82% | -25.31% |
Compare ZYME vs Peers
Zymeworks Inc. (ZYME) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ZYME Income Statement
Zymeworks Inc. (ZYME) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 51.76M | 53.02M | 29.54M | 38.95M | 26.68M | 412.48M | 76.01M | 76.3M | 105.97M | 81.26M |
Revenue Growth % | 370.18% | 2.43% | -44.28% | 31.84% | -31.5% | 1446.03% | -81.57% | 0.38% | 38.87% | -12.98% |
Cost of Goods Sold | 41.14M | 56.93M | 117.1M | 170.9M | 0 | 0 | 142.99M | 0 | 0 | 4.54M |
COGS % of Revenue | 79.49% | 107.37% | 396.34% | 438.75% | - | - | 188.11% | - | - | - |
Gross Profit | 10.62M▲ 0% | -3.91M▼ 136.8% | -87.55M▼ 2140.9% | -131.94M▼ 50.7% | 26.68M▲ 120.2% | 412.48M▲ 1446.0% | -66.98M▼ 116.2% | 76.3M▲ 213.9% | 105.97M▲ 38.9% | 76.72M▲ 0% |
Gross Margin % | 20.51% | -7.37% | -296.34% | -338.75% | 100% | 100% | -88.11% | 100% | 100% | 94.42% |
Gross Profit Growth % | 143.26% | -136.8% | -2140.9% | -50.7% | 120.22% | 1446.03% | -116.24% | 213.93% | 38.87% | - |
Operating Expenses | 59.22M | 86.15M | 63.75M | 55.52M | 242.31M | 281.95M | 71.08M | 213.41M | 198.5M | 190.78M |
OpEx % of Revenue | 114.42% | 162.48% | 215.78% | 142.55% | 908.22% | 68.36% | 93.51% | 279.69% | 187.33% | - |
Selling, General & Admin | 18.55M | 29.46M | 62.88M | 55.17M | 42.6M | 73.4M | 70.4M | 61.5M | 61.5M | 15.11B |
SG&A % of Revenue | 35.84% | 55.56% | 212.82% | 141.65% | 159.67% | 17.79% | 92.62% | 80.6% | 58.04% | - |
Research & Development | 41.75M | 56.68M | 118.25M | 171.34M | 199.75M | 208.6M | 143.62M | 134.62M | 137M | 2.51B |
R&D % of Revenue | 80.66% | 106.91% | 400.23% | 439.9% | 748.7% | 50.57% | 188.94% | 176.43% | 129.29% | - |
Other Operating Expenses | -964K | -1.26M | -117.37M | -171M | -39K | -42K | -142.94M | 17.29M | 0 | -903K |
Operating Income | -9M▲ 0% | -33.13M▼ 268.2% | -151.3M▼ 356.7% | -187.47M▼ 23.9% | -215.63M▼ 15.0% | 130.53M▲ 160.5% | -138.05M▼ 205.8% | -137.11M▲ 0.7% | -92.53M▲ 32.5% | -114.05M▲ 0% |
Operating Margin % | -17.38% | -62.48% | -512.12% | -481.29% | -808.22% | 31.64% | -181.62% | -179.69% | -87.33% | -140.35% |
Operating Income Growth % | 76.24% | -268.16% | -356.73% | -23.9% | -15.02% | 160.53% | -205.77% | 0.68% | 32.51% | - |
EBITDA | -6.26M | -29.5M | -148.99M | -184.11M | -206.05M | 142.53M | -120.75M | -125.92M | -81.42M | -117.82M |
EBITDA Margin % | -12.09% | -55.63% | -504.3% | -472.68% | -772.3% | 34.55% | -158.85% | -165.02% | -76.84% | -144.98% |
EBITDA Growth % | 83.01% | -371.27% | -405.1% | -23.57% | -11.92% | 169.17% | -184.72% | -4.28% | 35.33% | -4.51% |
D&A (Non-Cash Add-back) | 2.74M | 3.63M | 2.31M | 3.35M | 9.58M | 12M | 17.3M | 11.19M | 11.11M | -3.76M |
EBIT | -7.93M | -33.36M | -150.43M | -187.12M | -215.67M | 130.49M | -138.01M | -119.82M | -92.53M | -107.49M |
Net Interest Income | -397K | 2.47M | 5.88M | 5.7M | 1.97M | 3.6M | 19.7M | 19.94M | 13.35M | 10.57M |
Interest Income | 743K | 2.64M | 5.88M | 5.7M | 1.97M | 3.6M | 19.7M | 19.94M | 13.35M | 12.64M |
Interest Expense | 1.14M | 166K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.07M |
Other Income/Expense | -964K | -1.02M | 6.45M | 7.34M | 3.27M | 4.71M | 18.81M | 20.5M | 12.78M | 10.09M |
Pretax Income | -9.96M▲ 0% | -34.38M▼ 245.2% | -144.85M▼ 321.3% | -180.12M▼ 24.3% | -212.36M▼ 17.9% | 135.23M▲ 163.7% | -119.24M▼ 188.2% | -116.61M▲ 2.2% | -79.75M▲ 31.6% | -103.97M▲ 0% |
Pretax Margin % | -19.25% | -64.85% | -490.3% | -462.43% | -795.95% | 32.79% | -156.87% | -152.82% | -75.26% | -127.94% |
Income Tax | 444K | 2.17M | 582K | 429K | -516K | 10.89M | -568K | 6.08M | 1.38M | -1.31M |
Effective Tax Rate % | -4.46% | -6.31% | -0.4% | -0.24% | 0.24% | 8.05% | 0.48% | -5.22% | -1.73% | 1.26% |
Net Income | -10.41M▲ 0% | -36.56M▼ 251.3% | -145.44M▼ 297.8% | -180.55M▼ 24.1% | -211.84M▼ 17.3% | 124.34M▲ 158.7% | -118.67M▼ 195.4% | -122.69M▼ 3.4% | -81.13M▲ 33.9% | -102.66M▲ 0% |
Net Margin % | -20.1% | -68.95% | -492.27% | -463.54% | -794.01% | 30.14% | -156.13% | -160.8% | -76.56% | -126.33% |
Net Income Growth % | 69.22% | -251.3% | -297.85% | -24.14% | -17.33% | 158.69% | -195.44% | -3.39% | 33.88% | 9.7% |
Net Income (Continuing) | -10.41M | -36.56M | -145.44M | -180.55M | -211.84M | 124.34M | -118.67M | -122.69M | -81.13M | -102.66M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.49▲ 0% | -1.26▼ 157.1% | -3.83▼ 204.0% | -3.58▲ 6.5% | -4.61▼ 28.8% | 1.90▲ 141.2% | -1.72▼ 190.5% | -1.62▲ 5.8% | -1.08▲ 33.3% | -1.37▲ 0% |
EPS Growth % | 71.51% | -157.14% | -203.97% | 6.53% | -28.77% | 141.21% | -190.53% | 5.81% | 33.33% | 8.05% |
EPS (Basic) | -0.49 | -1.26 | -3.83 | -3.58 | -4.06 | 1.91 | -1.72 | -1.62 | -1.08 | - |
Diluted Shares Outstanding | 21.32M | 29.09M | 38.02M | 50.38M | 52.13M | 65.25M | 68.86M | 75.88M | 75.34M | 74.69M |
Basic Shares Outstanding | 21.25M | 29.01M | 37.97M | 50.38M | 52.13M | 65.19M | 68.86M | 75.85M | 75.34M | 74.67M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ZYME Balance Sheet
Zymeworks Inc. (ZYME) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 92.33M | 204.37M | 311.83M | 455.08M | 288.22M | 544.71M | 412.93M | 300.45M | 233.44M | 385.68B |
Cash & Short-Term Investments | 87.8M | 200.16M | 298.9M | 426.35M | 252.61M | 492.23M | 374.33M | 225.78M | 228.8M | 228.8M |
Cash Only | 35.95M | 42.2M | 128.45M | 242.04M | 201.87M | 400.91M | 157.56M | 66.1M | 41.16M | 41.16M |
Short-Term Investments | 51.85M | 157.96M | 170.45M | 184.32M | 50.74M | 91.32M | 216.77M | 159.67M | 187.64M | 120.44B |
Accounts Receivable | 2.33M | 358K | 2.19M | 15.29M | 15.61M | 33.4M | 19.48M | 55.81M | 4.64M | 4.67B |
Days Sales Outstanding | 16.43 | 2.46 | 26.99 | 143.31 | 213.61 | 29.56 | 93.53 | 266.99 | 15.98 | 5.29K |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 19.07M | 19.12M | 18.86M | 0 | 16.28B |
Total Non-Current Assets | 39.62M | 39.99M | 56.38M | 83.3M | 100.91M | 104.02M | 167.95M | 162.64M | 113.09M | 92.53B |
Property, Plant & Equipment | 7.18M | 6.48M | 16.5M | 17.61M | 49.77M | 47.65M | 37.54M | 34.32M | 0 | 28.87B |
Fixed Asset Turnover | 7.21x | 8.18x | 1.79x | 2.21x | 0.54x | 8.66x | 2.02x | 2.22x | - | 0.01x |
Goodwill | 12.02M | 12.02M | 12.02M | 12.02M | 12.02M | 12.02M | 12.02M | 12.02M | 12.02B | 12.02B |
Intangible Assets | 19.14M | 20.01M | 23.68M | 22.93M | 21.47M | 26.38M | 25.28M | 4.58M | 1.35B | 1.17B |
Long-Term Investments | 0 | 0 | 0 | 25.92M | 886K | 886K | 81.93M | 98.43M | 41.79M | 180.33M |
Other Non-Current Assets | 1.22M | 1.4M | 2.96M | 3.1M | 13.7M | 15.74M | 7.57M | 8.92M | -13.29B | 45.73B |
Total Assets | 131.96M▲ 0% | 244.36M▲ 85.2% | 368.2M▲ 50.7% | 538.38M▲ 46.2% | 389.13M▼ 27.7% | 648.73M▲ 66.7% | 580.88M▼ 10.5% | 463.09M▼ 20.3% | 346.53M▼ 25.2% | 478.21B▲ 0% |
Asset Turnover | 0.39x | 0.22x | 0.08x | 0.07x | 0.07x | 0.64x | 0.13x | 0.16x | 0.31x | 0.00x |
Asset Growth % | 40.39% | 85.19% | 50.68% | 46.22% | -27.72% | 66.71% | -10.46% | -20.28% | -25.17% | 112218.72% |
Total Current Liabilities | 14.66M | 29.99M | 82.55M | 85.67M | 71.85M | 95.63M | 55.76M | 88.29M | 42.32M | 35.65B |
Accounts Payable | 1.66M | 2.6M | 5.35M | 6.24M | 5.17M | 7.86M | 6.21M | 3.9M | 36.35M | 30.23M |
Days Payables Outstanding | 14.76 | 16.66 | 16.67 | 13.34 | - | - | 15.86 | - | - | 1.37K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.47M | 3.28B |
Deferred Revenue (Current) | 7.55M | 3.53M | 0 | 0 | 0 | 2.35M | 3.7M | 25.59M | 0 | 2.09B |
Other Current Liabilities | 2.04M | 20.63M | 50.59M | 48.74M | 11.1M | 16.01M | 8.68M | 7.49M | 2.5M | 30.26B |
Current Ratio | 6.30x | 6.82x | 3.78x | 5.31x | 4.01x | 5.70x | 7.41x | 3.40x | 5.52x | 10.82x |
Quick Ratio | 6.30x | 6.82x | 3.78x | 5.31x | 4.01x | 5.70x | 7.41x | 3.40x | 5.52x | 10.82x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 3.92K |
Total Non-Current Liabilities | 866K | 33.89M | 39.97M | 42.79M | 68.19M | 60.14M | 60.31M | 36.03M | 35.71M | 278.98B |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13.76B |
Capital Lease Obligations | 52K | 42K | 5.64M | 5.93M | 31.02M | 24.79M | 22.46M | 15.77M | 14.8M | 59.16M |
Deferred Tax Liabilities | 0 | 114K | 408K | 1.18M | 1.57M | 1.79M | 3.3M | 4.76M | 6.03M | 3.84B |
Other Non-Current Liabilities | 814K | 904K | 978K | 2.73M | 2.65M | 2.98M | 1.61M | 895K | 278K | 261.39B |
Total Liabilities | 15.53M | 63.87M | 122.52M | 128.45M | 140.04M | 155.77M | 116.07M | 124.32M | 78.03M | 314.63B |
Total Debt | 62K | 57K | 6.93M | 8.64M | 32.33M | 28.11M | 26.72M | 18.51M | 18.27M | 18.27M |
Net Debt | -35.88M | -42.15M | -121.52M | -233.39M | -169.53M | -372.8M | -130.84M | -47.6M | -22.89M | -22.89M |
Debt / Equity | 0.00x | - | 0.03x | 0.02x | 0.13x | 0.06x | 0.06x | 0.05x | 0.07x | 0.00x |
Debt / EBITDA | - | - | - | - | - | 0.20x | - | - | - | -0.16x |
Net Debt / EBITDA | - | - | - | - | - | -2.62x | - | - | - | 0.19x |
Interest Coverage | -6.96x | -200.99x | - | - | - | - | - | - | - | -52.03x |
Total Equity | 116.43M▲ 0% | -145.27M▼ 224.8% | 245.68M▲ 269.1% | 409.92M▲ 66.9% | 249.09M▼ 39.2% | 492.96M▲ 97.9% | 464.81M▼ 5.7% | 338.77M▼ 27.1% | 268.5M▼ 20.7% | 163.59B▲ 0% |
Equity Growth % | 1193.36% | -224.77% | 269.12% | 66.85% | -39.23% | 97.9% | -5.71% | -27.12% | -20.74% | 50189.02% |
Book Value per Share | 5.46 | -4.99 | 6.46 | 8.14 | 4.78 | 7.55 | 6.75 | 4.46 | 3.56 | 2190.09 |
Total Shareholders' Equity | 116.43M | -145.27M | 245.68M | 409.92M | 249.09M | 492.96M | 464.81M | 338.77M | 268.5M | 163.59B |
Common Stock | 222.99M | 320.07M | 450.21M | 724.22M | 741.15M | 906.76M | 1.01B | 1.02B | 1.11B | 1.13T |
Retained Earnings | -108.72M | -145.27M | -290.71M | -471.26M | -683.1M | -558.76M | -677.44M | -830.34M | -953.16M | -1.07T |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -6.66M | -6.66M | -6.66M | -6.66M | -6.66M | -6.66M | -6.6M | -6.95M | -6.08M | -6.57B |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ZYME Cash Flow Statement
Zymeworks Inc. (ZYME) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 219K | 24.18M | -81.85M | -151.4M | -192.45M | 144.11M | -118.3M | -110.04M | -33.01M | -45.75B |
Operating CF Margin % | 0.42% | 45.6% | -277.05% | -388.7% | -721.33% | 34.94% | -155.64% | -144.22% | -31.15% | - |
Operating CF Growth % | 100.62% | 10939.73% | -438.56% | -84.97% | -27.11% | 174.88% | -182.09% | 6.98% | 70.01% | -1341995.41% |
Net Income | -10.41M | -36.56M | -145.44M | -180.55M | -211.84M | 124.34M | -118.67M | -122.69M | -81.13M | -102.66M |
Depreciation & Amortization | 2.74M | 3.63M | 7.33M | 10.28M | 9.58M | 12M | 17.3M | 11.19M | 10.79M | 1.15B |
Stock-Based Compensation | 3.43M | 13.44M | 49M | 29.12M | 10.76M | 4.01M | 8.1M | 17.79M | 28.03M | 6.94B |
Deferred Taxes | 15K | -17K | -726K | 266K | -953K | 1.94M | -757K | 691K | 945K | -2.2B |
Other Non-Cash Items | 2.66M | 3.75M | 1.54M | -364K | -387K | -2.21M | 1.27M | 13.93M | 848K | -7.41B |
Working Capital Changes | 1.78M | 39.92M | 6.44M | -10.15M | 393K | 4.01M | -25.55M | -30.95M | 7.5M | -13.15M |
Change in Receivables | 2.41M | -119K | -1.83M | -13.11M | -266K | -17.51M | 13.92M | -36.36M | 51.2M | 19.65M |
Change in Inventory | 0 | -111K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -358K | 3.68M | 21.57M | 7.62M | 16.48M | 26.48M | -44.77M | 14.34M | -23.65M | -9.85M |
Cash from Investing | -30.89M | -109.05M | -25.59M | -43.44M | 144.6M | -53.85M | -207.25M | 38.76M | 26.66M | 69.97B |
Capital Expenditures | -3.12M | -3.42M | -6.32M | -6.26M | -12.4M | -13.13M | -2.47M | -1.99M | -2.35M | -1.84M |
CapEx % of Revenue | 6.03% | 6.45% | 21.4% | 16.08% | 46.49% | 3.18% | 3.25% | 2.61% | 2.22% | 2.26% |
Acquisitions | 0 | 0 | 0 | 1.96M | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -27.77M | -105.63M | -7.56M | -1.96M | -881K | 40.72M | -1.6M | -1.07M | 0 | 69.89B |
Cash from Financing | 49.95M | 91.43M | 193.66M | 308.98M | 8.01M | 108.58M | 81.85M | -20.45M | -18.56M | 178.77B |
Debt Issued (Net) | -7.82M | -11K | -16K | -41K | -17K | -14K | -21K | -14K | 0 | 245.61M |
Equity Issued (Net) | 55.79M | 90.75M | 188.23M | 300.91M | 0 | 107.53M | 76.09M | -30.05M | -18.38M | -84.09M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -30.05M | -41.7M | -101.47M |
Other Financing | 1.98M | 690K | 5.45M | 8.11M | 8.03M | 1.06M | 5.77M | 9.61M | -181K | 178.6B |
Net Change in Cash | 19.51M▲ 0% | 6.26M▼ 67.9% | 86.25M▲ 1278.0% | 113.58M▲ 31.7% | -40.17M▼ 135.4% | 199.04M▲ 595.5% | -243.35M▼ 222.3% | -91.45M▲ 62.4% | -24.95M▲ 72.7% | 203.09B▲ 0% |
Free Cash Flow | -2.9M▲ 0% | 20.76M▲ 815.3% | -95.73M▼ 561.2% | -157.67M▼ 64.7% | -205.74M▼ 30.5% | 130.98M▲ 163.7% | -122.38M▼ 193.4% | -113.11M▲ 7.6% | -34.53M▲ 69.5% | -45.75B▲ 0% |
FCF Margin % | -5.61% | 39.15% | -324.03% | -404.79% | -771.12% | 31.76% | -161% | -148.24% | -32.58% | -56297.68% |
FCF Growth % | 92.87% | 815.27% | -561.2% | -64.7% | -30.49% | 163.67% | -193.43% | 7.57% | 69.48% | -58159.92% |
FCF per Share | -0.14 | 0.71 | -2.52 | -3.13 | -3.95 | 2.01 | -1.78 | -1.49 | -0.46 | -612.48 |
FCF Conversion (FCF/Net Income) | -0.02x | -0.66x | 0.56x | 0.84x | 0.91x | 1.16x | 1.00x | 0.90x | 0.41x | 445.66x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.18M | 0 | 856K |
ZYME Key Ratios
Zymeworks Inc. (ZYME) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -16.59% | - | -289.69% | -55.08% | -64.29% | 33.51% | -24.78% | -30.54% | -26.72% | -0.25% |
Return on Invested Capital (ROIC) | -17.41% | - | -91.4% | -93.52% | -126.3% | 98.03% | -45.6% | -32.9% | -25.86% | -0.21% |
Gross Margin | 20.51% | -7.37% | -296.34% | -338.75% | 100% | 100% | -88.11% | 100% | 100% | 94.42% |
Net Margin | -20.1% | -68.95% | -492.27% | -463.54% | -794.01% | 30.14% | -156.13% | -160.8% | -76.56% | -126.33% |
Debt / Equity | 0.00x | - | 0.03x | 0.02x | 0.13x | 0.06x | 0.06x | 0.05x | 0.07x | 0.00x |
Interest Coverage | -6.96x | -200.99x | - | - | - | - | - | - | - | -52.03x |
FCF Conversion | -0.02x | -0.66x | 0.56x | 0.84x | 0.91x | 1.16x | 1.00x | 0.90x | 0.41x | 445.66x |
Revenue Growth | 370.18% | 2.43% | -44.28% | 31.84% | -31.5% | 1446.03% | -81.57% | 0.38% | 38.87% | -12.98% |
Related:ZYME Dividend History·ZYME Revenue History·ZYME Price History·ZYME P/E History·ZYME Financial Ratios·ZYME Institutional Holders
ZYME SEC Filings & Documents
Zymeworks Inc. (ZYME) SEC filings — annual & quarterly reports (10-K, 10-Q)
ZYME Frequently Asked Questions
Zymeworks Inc. (ZYME) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Zymeworks Inc. (ZYME) reported $81.3M in revenue for fiscal year 2025. This represents a 4766% increase from $1.7M in 2014.
Zymeworks Inc. (ZYME) grew revenue by 38.9% over the past year. This is strong growth.
Zymeworks Inc. (ZYME) reported a net loss of $102.7M for fiscal year 2025.
Dividend & Returns
Zymeworks Inc. (ZYME) has a return on equity (ROE) of -26.7%. Negative ROE indicates the company is unprofitable.
Zymeworks Inc. (ZYME) had negative free cash flow of $45.75B in fiscal year 2025, likely due to heavy capital investments.